 Lisa Bero
Concepts (713)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Conflict of Interest | 85 | 2025 | 123 | 22.650 |
Why?
| | Drug Industry | 63 | 2025 | 106 | 16.920 |
Why?
| | Research Support as Topic | 40 | 2024 | 111 | 9.080 |
Why?
| | Tobacco Industry | 35 | 2018 | 46 | 7.910 |
Why?
| | Industry | 27 | 2024 | 63 | 6.170 |
Why?
| | Publication Bias | 25 | 2024 | 35 | 6.020 |
Why?
| | Research Design | 39 | 2024 | 1036 | 5.980 |
Why?
| | Publishing | 36 | 2024 | 140 | 5.860 |
Why?
| | Disclosure | 29 | 2022 | 110 | 5.540 |
Why?
| | Review Literature as Topic | 24 | 2023 | 66 | 5.310 |
Why?
| | Health Policy | 24 | 2022 | 352 | 4.940 |
Why?
| | Biomedical Research | 26 | 2025 | 635 | 4.910 |
Why?
| | Public Health | 30 | 2024 | 482 | 4.770 |
Why?
| | Evidence-Based Medicine | 29 | 2024 | 711 | 4.770 |
Why?
| | World Health Organization | 23 | 2022 | 110 | 4.530 |
Why?
| | Policy Making | 21 | 2022 | 88 | 4.390 |
Why?
| | Practice Guidelines as Topic | 22 | 2021 | 1478 | 3.820 |
Why?
| | Meta-Analysis as Topic | 18 | 2024 | 169 | 3.770 |
Why?
| | Bias | 21 | 2024 | 195 | 3.500 |
Why?
| | Randomized Controlled Trials as Topic | 26 | 2024 | 1356 | 3.390 |
Why?
| | Scientific Misconduct | 6 | 2024 | 12 | 3.150 |
Why?
| | Pharmaceutical Preparations | 10 | 2022 | 168 | 3.010 |
Why?
| | Mobile Applications | 8 | 2020 | 159 | 2.890 |
Why?
| | Australia | 25 | 2023 | 245 | 2.820 |
Why?
| | Smoking | 27 | 2016 | 1460 | 2.660 |
Why?
| | Nutritional Sciences | 7 | 2024 | 41 | 2.640 |
Why?
| | Editorial Policies | 10 | 2021 | 48 | 2.640 |
Why?
| | Periodicals as Topic | 19 | 2020 | 204 | 2.420 |
Why?
| | Humans | 276 | 2025 | 128417 | 2.390 |
Why?
| | Smoking Prevention | 13 | 2012 | 162 | 2.390 |
Why?
| | Environmental Exposure | 7 | 2025 | 461 | 2.330 |
Why?
| | Food Industry | 8 | 2024 | 16 | 2.320 |
Why?
| | Health Personnel | 11 | 2024 | 644 | 2.260 |
Why?
| | Environmental Health | 8 | 2025 | 37 | 2.190 |
Why?
| | Nutrition Policy | 5 | 2020 | 56 | 2.130 |
Why?
| | Observational Studies as Topic | 6 | 2024 | 108 | 2.070 |
Why?
| | Clinical Trials as Topic | 18 | 2021 | 993 | 2.070 |
Why?
| | Marketing | 10 | 2024 | 28 | 2.030 |
Why?
| | Research Report | 5 | 2019 | 73 | 2.020 |
Why?
| | Equipment and Supplies | 8 | 2020 | 41 | 2.020 |
Why?
| | Information Dissemination | 10 | 2021 | 204 | 1.910 |
Why?
| | Guideline Adherence | 8 | 2019 | 521 | 1.840 |
Why?
| | United States Food and Drug Administration | 14 | 2015 | 199 | 1.820 |
Why?
| | Tobacco Smoke Pollution | 17 | 2006 | 229 | 1.740 |
Why?
| | Qualitative Research | 14 | 2025 | 1226 | 1.740 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2018 | 413 | 1.660 |
Why?
| | Ethics, Research | 5 | 2020 | 30 | 1.640 |
Why?
| | Peer Review, Research | 11 | 2025 | 41 | 1.630 |
Why?
| | Government Regulation | 13 | 2019 | 49 | 1.590 |
Why?
| | Environmental Pollutants | 6 | 2018 | 142 | 1.580 |
Why?
| | Research | 19 | 2020 | 411 | 1.530 |
Why?
| | Drugs, Essential | 5 | 2018 | 6 | 1.530 |
Why?
| | Propaganda | 3 | 2019 | 3 | 1.510 |
Why?
| | Public Policy | 7 | 2016 | 68 | 1.500 |
Why?
| | Research Personnel | 6 | 2024 | 156 | 1.470 |
Why?
| | Authorship | 11 | 2024 | 45 | 1.460 |
Why?
| | United States | 69 | 2025 | 13830 | 1.450 |
Why?
| | Politics | 9 | 2020 | 91 | 1.420 |
Why?
| | Cross-Sectional Studies | 30 | 2024 | 5039 | 1.370 |
Why?
| | Bibliometrics | 6 | 2018 | 53 | 1.350 |
Why?
| | Data Collection | 9 | 2019 | 647 | 1.340 |
Why?
| | Coronavirus Infections | 4 | 2021 | 337 | 1.240 |
Why?
| | Evidence-Based Practice | 4 | 2020 | 209 | 1.230 |
Why?
| | Guidelines as Topic | 7 | 2020 | 260 | 1.220 |
Why?
| | Physicians | 12 | 2023 | 858 | 1.220 |
Why?
| | Nutritional Status | 5 | 2020 | 325 | 1.220 |
Why?
| | Delivery of Health Care | 5 | 2024 | 895 | 1.180 |
Why?
| | Occupational Health | 6 | 2019 | 196 | 1.150 |
Why?
| | Pharmacy and Therapeutics Committee | 2 | 2020 | 2 | 1.140 |
Why?
| | Commerce | 8 | 2020 | 69 | 1.120 |
Why?
| | Policy | 4 | 2022 | 143 | 1.090 |
Why?
| | Community Pharmacy Services | 2 | 2022 | 45 | 1.090 |
Why?
| | Vitamin D | 2 | 2021 | 380 | 1.090 |
Why?
| | Advanced Practice Nursing | 2 | 2025 | 31 | 1.070 |
Why?
| | Risk Management | 2 | 2022 | 85 | 1.060 |
Why?
| | Interprofessional Relations | 5 | 2021 | 274 | 1.050 |
Why?
| | Diet | 6 | 2024 | 1199 | 1.040 |
Why?
| | Health Promotion | 8 | 2019 | 716 | 1.030 |
Why?
| | Decision Making | 11 | 2025 | 847 | 1.030 |
Why?
| | Workplace | 5 | 2009 | 246 | 1.030 |
Why?
| | Education, Medical, Continuing | 4 | 2019 | 121 | 1.020 |
Why?
| | Drug Approval | 5 | 2015 | 86 | 1.020 |
Why?
| | Cardiovascular Diseases | 7 | 2021 | 1999 | 0.990 |
Why?
| | Bone and Bones | 2 | 2021 | 299 | 0.990 |
Why?
| | Deprescriptions | 5 | 2023 | 34 | 0.960 |
Why?
| | Lobbying | 6 | 2006 | 8 | 0.960 |
Why?
| | Interrupted Time Series Analysis | 7 | 2022 | 52 | 0.940 |
Why?
| | Practice Patterns, Physicians' | 12 | 2021 | 1258 | 0.930 |
Why?
| | Toxicity Tests | 3 | 2016 | 28 | 0.900 |
Why?
| | Financial Support | 5 | 2019 | 19 | 0.900 |
Why?
| | Medical Overuse | 4 | 2019 | 30 | 0.890 |
Why?
| | Risk Assessment | 10 | 2022 | 3232 | 0.890 |
Why?
| | Spinal Cord Stimulation | 1 | 2024 | 8 | 0.890 |
Why?
| | Consumer Advocacy | 2 | 2020 | 13 | 0.850 |
Why?
| | Formularies as Topic | 3 | 2018 | 6 | 0.840 |
Why?
| | Pandemics | 7 | 2023 | 1476 | 0.840 |
Why?
| | Codeine | 1 | 2022 | 5 | 0.830 |
Why?
| | Telemedicine | 4 | 2019 | 782 | 0.830 |
Why?
| | Health Education | 2 | 2018 | 333 | 0.790 |
Why?
| | Epidemiologic Methods | 2 | 2022 | 73 | 0.790 |
Why?
| | Health Priorities | 2 | 2012 | 34 | 0.780 |
Why?
| | Drug Evaluation | 5 | 2012 | 81 | 0.780 |
Why?
| | Dietary Supplements | 2 | 2021 | 531 | 0.780 |
Why?
| | Nursing Care | 1 | 2022 | 38 | 0.780 |
Why?
| | Confidentiality | 2 | 2021 | 67 | 0.760 |
Why?
| | Tobacco Products | 4 | 2018 | 110 | 0.750 |
Why?
| | Retraction of Publication as Topic | 1 | 2021 | 1 | 0.750 |
Why?
| | Recommended Dietary Allowances | 1 | 2021 | 19 | 0.740 |
Why?
| | Group Practice | 1 | 2021 | 7 | 0.730 |
Why?
| | Attitude | 4 | 2013 | 249 | 0.720 |
Why?
| | Advisory Committees | 6 | 2020 | 218 | 0.720 |
Why?
| | Bone Remodeling | 1 | 2021 | 71 | 0.710 |
Why?
| | Technology Transfer | 2 | 2019 | 11 | 0.710 |
Why?
| | Contact Tracing | 1 | 2020 | 23 | 0.700 |
Why?
| | Betacoronavirus | 2 | 2020 | 251 | 0.700 |
Why?
| | Interviews as Topic | 7 | 2019 | 715 | 0.690 |
Why?
| | Gift Giving | 2 | 2019 | 11 | 0.690 |
Why?
| | Selection Bias | 3 | 2024 | 37 | 0.690 |
Why?
| | Checklist | 1 | 2021 | 95 | 0.680 |
Why?
| | Calcium | 2 | 2021 | 1178 | 0.680 |
Why?
| | Societies, Scientific | 1 | 2020 | 46 | 0.680 |
Why?
| | Atherosclerosis | 2 | 2015 | 403 | 0.680 |
Why?
| | Science | 3 | 2007 | 50 | 0.680 |
Why?
| | Societies | 1 | 2020 | 36 | 0.670 |
Why?
| | Beverages | 2 | 2019 | 67 | 0.670 |
Why?
| | Organizational Policy | 7 | 2011 | 76 | 0.670 |
Why?
| | Public Opinion | 7 | 2015 | 63 | 0.660 |
Why?
| | Pharmacists | 8 | 2022 | 261 | 0.660 |
Why?
| | Attitude to Health | 6 | 2015 | 431 | 0.660 |
Why?
| | Dental Research | 1 | 2019 | 5 | 0.650 |
Why?
| | Marketing of Health Services | 3 | 2018 | 14 | 0.650 |
Why?
| | Calcium, Dietary | 1 | 2019 | 56 | 0.650 |
Why?
| | Whole Grains | 1 | 2019 | 3 | 0.650 |
Why?
| | Off-Label Use | 3 | 2015 | 51 | 0.650 |
Why?
| | Patient Advocacy | 2 | 2019 | 74 | 0.640 |
Why?
| | Databases, Factual | 5 | 2020 | 1269 | 0.630 |
Why?
| | Hazardous Substances | 2 | 2018 | 13 | 0.620 |
Why?
| | Tobacco Use Disorder | 4 | 2010 | 239 | 0.620 |
Why?
| | Gynecology | 1 | 2021 | 175 | 0.620 |
Why?
| | International Cooperation | 7 | 2011 | 171 | 0.620 |
Why?
| | Internet | 4 | 2019 | 617 | 0.610 |
Why?
| | Analgesics, Opioid | 7 | 2023 | 887 | 0.600 |
Why?
| | Journalism | 2 | 2012 | 7 | 0.600 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 341 | 0.600 |
Why?
| | Professional Role | 4 | 2022 | 160 | 0.600 |
Why?
| | Vitamins | 1 | 2019 | 174 | 0.600 |
Why?
| | Health Behavior | 4 | 2021 | 741 | 0.600 |
Why?
| | Nicotine | 8 | 2006 | 303 | 0.600 |
Why?
| | Quality Control | 8 | 2013 | 156 | 0.590 |
Why?
| | Food Analysis | 1 | 2018 | 21 | 0.590 |
Why?
| | Fluorocarbons | 2 | 2023 | 109 | 0.590 |
Why?
| | Access to Information | 3 | 2014 | 47 | 0.590 |
Why?
| | Developing Countries | 4 | 2018 | 285 | 0.590 |
Why?
| | Pharmaceutical Services | 3 | 2013 | 83 | 0.590 |
Why?
| | Cooperative Behavior | 3 | 2013 | 432 | 0.580 |
Why?
| | Health Services | 3 | 2013 | 99 | 0.580 |
Why?
| | Writing | 2 | 2019 | 91 | 0.580 |
Why?
| | Capital Financing | 1 | 2017 | 7 | 0.580 |
Why?
| | Databases, Bibliographic | 3 | 2014 | 30 | 0.580 |
Why?
| | Population Health | 1 | 2018 | 46 | 0.560 |
Why?
| | Disease Outbreaks | 1 | 2020 | 341 | 0.560 |
Why?
| | Nurses | 2 | 2016 | 164 | 0.550 |
Why?
| | Vaccines | 1 | 2022 | 393 | 0.540 |
Why?
| | Interinstitutional Relations | 5 | 2013 | 57 | 0.540 |
Why?
| | Peer Review | 5 | 2015 | 47 | 0.540 |
Why?
| | Cannabis | 1 | 2023 | 429 | 0.540 |
Why?
| | Obesity | 4 | 2023 | 2858 | 0.540 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2015 | 168 | 0.540 |
Why?
| | Government Agencies | 2 | 2015 | 15 | 0.530 |
Why?
| | Primary Prevention | 1 | 2018 | 185 | 0.530 |
Why?
| | Models, Organizational | 3 | 2008 | 145 | 0.530 |
Why?
| | Tobacco Use Cessation | 1 | 2016 | 24 | 0.530 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 480 | 0.530 |
Why?
| | Sweetening Agents | 1 | 2016 | 38 | 0.520 |
Why?
| | Drug Prescriptions | 4 | 2022 | 248 | 0.510 |
Why?
| | Atrazine | 1 | 2015 | 8 | 0.510 |
Why?
| | California | 9 | 2013 | 398 | 0.510 |
Why?
| | Libraries, Digital | 2 | 2012 | 4 | 0.500 |
Why?
| | Drug Overdose | 1 | 2020 | 319 | 0.500 |
Why?
| | Air Pollution, Indoor | 3 | 2009 | 144 | 0.500 |
Why?
| | Pharmacies | 1 | 2015 | 37 | 0.490 |
Why?
| | Medicaid | 4 | 2013 | 433 | 0.490 |
Why?
| | Databases, Pharmaceutical | 1 | 2015 | 5 | 0.490 |
Why?
| | Patient Care Planning | 1 | 2016 | 149 | 0.480 |
Why?
| | Fees, Pharmaceutical | 2 | 2014 | 10 | 0.480 |
Why?
| | Epidemiologic Studies | 2 | 2022 | 65 | 0.480 |
Why?
| | Information Services | 4 | 2002 | 46 | 0.480 |
Why?
| | Fetal Development | 2 | 2016 | 283 | 0.470 |
Why?
| | Cohort Studies | 7 | 2022 | 5388 | 0.470 |
Why?
| | Anticoagulants | 1 | 2019 | 613 | 0.470 |
Why?
| | Medication Adherence | 1 | 2019 | 560 | 0.470 |
Why?
| | Academic Medical Centers | 4 | 2018 | 476 | 0.470 |
Why?
| | Canada | 7 | 2022 | 344 | 0.470 |
Why?
| | Caprylates | 1 | 2014 | 22 | 0.460 |
Why?
| | Knowledge | 2 | 2012 | 51 | 0.460 |
Why?
| | Quality of Health Care | 4 | 2012 | 606 | 0.450 |
Why?
| | Treatment Outcome | 16 | 2018 | 10151 | 0.450 |
Why?
| | Expert Testimony | 3 | 2020 | 36 | 0.450 |
Why?
| | Teaching Materials | 2 | 2007 | 23 | 0.450 |
Why?
| | Universities | 4 | 2007 | 400 | 0.440 |
Why?
| | Occupational Exposure | 3 | 2022 | 310 | 0.430 |
Why?
| | Mass Media | 5 | 2001 | 40 | 0.420 |
Why?
| | Depressive Disorder, Major | 1 | 2017 | 342 | 0.420 |
Why?
| | Social Support | 1 | 2017 | 589 | 0.420 |
Why?
| | Cyclohexanecarboxylic Acids | 3 | 2009 | 21 | 0.420 |
Why?
| | Counseling | 1 | 2016 | 382 | 0.420 |
Why?
| | Community Participation | 2 | 2010 | 125 | 0.420 |
Why?
| | Amines | 3 | 2009 | 37 | 0.420 |
Why?
| | Ambulatory Care | 3 | 2010 | 503 | 0.420 |
Why?
| | Financial Management | 3 | 2012 | 15 | 0.410 |
Why?
| | Substance-Related Disorders | 7 | 2016 | 1013 | 0.410 |
Why?
| | Angiogenesis Inhibitors | 1 | 2014 | 215 | 0.410 |
Why?
| | Documentation | 5 | 2018 | 181 | 0.410 |
Why?
| | Macular Degeneration | 1 | 2014 | 157 | 0.400 |
Why?
| | Carcinogens | 2 | 2020 | 110 | 0.400 |
Why?
| | Cholesterol, LDL | 1 | 2014 | 360 | 0.400 |
Why?
| | Thinking | 1 | 2013 | 56 | 0.400 |
Why?
| | Infant Formula | 2 | 2024 | 74 | 0.390 |
Why?
| | gamma-Aminobutyric Acid | 3 | 2009 | 158 | 0.390 |
Why?
| | Overweight | 1 | 2016 | 524 | 0.390 |
Why?
| | Body Weight | 1 | 2016 | 928 | 0.390 |
Why?
| | Device Approval | 4 | 2015 | 21 | 0.390 |
Why?
| | Medication Therapy Management | 1 | 2013 | 74 | 0.390 |
Why?
| | Attitude of Health Personnel | 7 | 2023 | 1093 | 0.380 |
Why?
| | Federal Government | 3 | 2009 | 26 | 0.380 |
Why?
| | Global Health | 3 | 2020 | 327 | 0.380 |
Why?
| | Human Experimentation | 2 | 2009 | 12 | 0.370 |
Why?
| | Publications | 3 | 2020 | 41 | 0.370 |
Why?
| | Health Services Accessibility | 4 | 2015 | 896 | 0.370 |
Why?
| | Birth Weight | 1 | 2014 | 498 | 0.360 |
Why?
| | Oncologists | 2 | 2021 | 35 | 0.360 |
Why?
| | Organizations, Nonprofit | 1 | 2011 | 17 | 0.360 |
Why?
| | Neoplasms | 9 | 2023 | 2464 | 0.360 |
Why?
| | Prejudice | 3 | 2017 | 68 | 0.360 |
Why?
| | Thrombosis | 1 | 2014 | 324 | 0.360 |
Why?
| | Health Knowledge, Attitudes, Practice | 6 | 2021 | 1275 | 0.350 |
Why?
| | Decision Making, Organizational | 2 | 2007 | 26 | 0.350 |
Why?
| | Patient Education as Topic | 2 | 2013 | 737 | 0.350 |
Why?
| | Relief Work | 1 | 2010 | 20 | 0.350 |
Why?
| | Teaching | 1 | 2013 | 215 | 0.350 |
Why?
| | Decision Support Techniques | 1 | 2014 | 396 | 0.350 |
Why?
| | Public Relations | 5 | 2017 | 6 | 0.340 |
Why?
| | Child Welfare | 1 | 2012 | 211 | 0.340 |
Why?
| | Drug Labeling | 2 | 2013 | 41 | 0.330 |
Why?
| | Congresses as Topic | 4 | 1997 | 212 | 0.330 |
Why?
| | Cluster Analysis | 1 | 2011 | 478 | 0.330 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2014 | 253 | 0.330 |
Why?
| | Health Care Sector | 2 | 2020 | 24 | 0.330 |
Why?
| | Prescription Drugs | 4 | 2017 | 112 | 0.330 |
Why?
| | Patient Satisfaction | 4 | 2017 | 641 | 0.330 |
Why?
| | Health Care Costs | 4 | 2019 | 367 | 0.320 |
Why?
| | Women's Health | 1 | 2012 | 362 | 0.320 |
Why?
| | Economic Development | 1 | 2009 | 3 | 0.320 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 755 | 0.320 |
Why?
| | Ethics, Institutional | 1 | 2009 | 4 | 0.320 |
Why?
| | Occupational Diseases | 2 | 2022 | 138 | 0.320 |
Why?
| | Social Control Policies | 1 | 2008 | 1 | 0.320 |
Why?
| | Ethics, Professional | 1 | 2009 | 15 | 0.310 |
Why?
| | Restaurants | 1 | 2008 | 19 | 0.310 |
Why?
| | Life Style | 2 | 2021 | 460 | 0.310 |
Why?
| | Poverty | 2 | 2010 | 496 | 0.310 |
Why?
| | Law Enforcement | 1 | 2008 | 39 | 0.300 |
Why?
| | Thiazolidinediones | 1 | 2009 | 137 | 0.300 |
Why?
| | Morals | 1 | 2009 | 71 | 0.290 |
Why?
| | Laboratories | 1 | 2009 | 109 | 0.290 |
Why?
| | Trust | 2 | 2019 | 116 | 0.290 |
Why?
| | Uncertainty | 2 | 2021 | 114 | 0.280 |
Why?
| | Ethics Committees, Research | 1 | 2007 | 41 | 0.280 |
Why?
| | Research Subjects | 1 | 2007 | 42 | 0.280 |
Why?
| | Drug and Narcotic Control | 3 | 2021 | 28 | 0.280 |
Why?
| | Privacy | 3 | 2020 | 32 | 0.280 |
Why?
| | Consumer Organizations | 1 | 2007 | 1 | 0.280 |
Why?
| | Plants, Toxic | 6 | 1995 | 22 | 0.280 |
Why?
| | Osteoporosis | 3 | 2021 | 233 | 0.280 |
Why?
| | Nutritional Physiological Phenomena | 2 | 2017 | 53 | 0.270 |
Why?
| | Deception | 1 | 2007 | 18 | 0.270 |
Why?
| | Minority Groups | 1 | 2009 | 251 | 0.270 |
Why?
| | Smoking Cessation | 5 | 2018 | 408 | 0.270 |
Why?
| | Europe | 4 | 2021 | 359 | 0.270 |
Why?
| | Female | 26 | 2025 | 68153 | 0.270 |
Why?
| | Books | 1 | 2006 | 3 | 0.270 |
Why?
| | Aircraft | 1 | 2006 | 22 | 0.260 |
Why?
| | Aerospace Medicine | 1 | 2006 | 23 | 0.260 |
Why?
| | Health Status Disparities | 1 | 2009 | 254 | 0.260 |
Why?
| | United States Dept. of Health and Human Services | 1 | 2006 | 2 | 0.260 |
Why?
| | Animals | 21 | 2024 | 34479 | 0.250 |
Why?
| | Adolescent Behavior | 2 | 2002 | 505 | 0.250 |
Why?
| | Nonprescription Drugs | 1 | 2006 | 66 | 0.250 |
Why?
| | Consumer Product Safety | 3 | 2019 | 30 | 0.250 |
Why?
| | Disease | 2 | 2019 | 95 | 0.250 |
Why?
| | Insurance Claim Reporting | 1 | 2005 | 21 | 0.250 |
Why?
| | MEDLINE | 3 | 2014 | 20 | 0.250 |
Why?
| | Drug Utilization | 3 | 2022 | 166 | 0.240 |
Why?
| | Data Interpretation, Statistical | 3 | 2017 | 335 | 0.240 |
Why?
| | Bone Density | 1 | 2009 | 474 | 0.240 |
Why?
| | Adult | 12 | 2025 | 35299 | 0.230 |
Why?
| | Animal Experimentation | 1 | 2024 | 6 | 0.230 |
Why?
| | Harm Reduction | 1 | 2004 | 31 | 0.230 |
Why?
| | Animals, Laboratory | 1 | 2024 | 17 | 0.230 |
Why?
| | Pharmacy Service, Hospital | 3 | 2002 | 93 | 0.230 |
Why?
| | International Classification of Diseases | 1 | 2005 | 123 | 0.230 |
Why?
| | Education | 1 | 2025 | 100 | 0.230 |
Why?
| | Case-Control Studies | 2 | 2024 | 3328 | 0.220 |
Why?
| | Health Care Surveys | 3 | 2013 | 555 | 0.220 |
Why?
| | Depression | 2 | 2003 | 1294 | 0.220 |
Why?
| | Evaluation Studies as Topic | 3 | 2019 | 171 | 0.220 |
Why?
| | Primary Health Care | 3 | 2020 | 1668 | 0.220 |
Why?
| | Cost-Benefit Analysis | 4 | 2015 | 567 | 0.220 |
Why?
| | Receptors, Opioid | 3 | 1988 | 20 | 0.220 |
Why?
| | Consultants | 2 | 2020 | 13 | 0.220 |
Why?
| | Antihypertensive Agents | 1 | 2007 | 485 | 0.220 |
Why?
| | Male | 21 | 2023 | 62857 | 0.220 |
Why?
| | Data Accuracy | 2 | 2021 | 57 | 0.220 |
Why?
| | Quarantine | 2 | 2020 | 27 | 0.210 |
Why?
| | Data Mining | 2 | 2015 | 109 | 0.210 |
Why?
| | Sample Size | 2 | 2014 | 115 | 0.210 |
Why?
| | Schizophrenia | 1 | 2007 | 428 | 0.210 |
Why?
| | Journal Impact Factor | 3 | 2020 | 29 | 0.210 |
Why?
| | Public Health Practice | 2 | 2010 | 64 | 0.210 |
Why?
| | Prolactin | 4 | 1987 | 97 | 0.210 |
Why?
| | State Government | 3 | 2009 | 43 | 0.210 |
Why?
| | Drug Therapy | 5 | 2011 | 77 | 0.210 |
Why?
| | Private Sector | 2 | 2000 | 50 | 0.210 |
Why?
| | Estonia | 2 | 2012 | 2 | 0.210 |
Why?
| | Nurse Practitioners | 1 | 2025 | 127 | 0.200 |
Why?
| | Datasets as Topic | 2 | 2020 | 109 | 0.200 |
Why?
| | Dronabinol | 1 | 2024 | 166 | 0.200 |
Why?
| | Health Status | 2 | 2021 | 755 | 0.200 |
Why?
| | Risk | 2 | 2016 | 853 | 0.200 |
Why?
| | Fraud | 1 | 2022 | 9 | 0.200 |
Why?
| | Program Development | 2 | 2016 | 360 | 0.200 |
Why?
| | Analgesics | 1 | 2023 | 163 | 0.200 |
Why?
| | Food | 2 | 2024 | 155 | 0.200 |
Why?
| | Libraries, Medical | 1 | 2002 | 10 | 0.200 |
Why?
| | Mental Health | 2 | 2019 | 686 | 0.190 |
Why?
| | Torsades de Pointes | 1 | 2022 | 21 | 0.190 |
Why?
| | Alcohol Drinking | 1 | 2008 | 752 | 0.190 |
Why?
| | Newspapers as Topic | 2 | 2001 | 10 | 0.190 |
Why?
| | Truth Disclosure | 7 | 2011 | 44 | 0.190 |
Why?
| | Chemical Industry | 2 | 2013 | 11 | 0.190 |
Why?
| | Program Evaluation | 4 | 2020 | 874 | 0.190 |
Why?
| | History, 21st Century | 2 | 2018 | 181 | 0.190 |
Why?
| | Risk Factors | 7 | 2022 | 9704 | 0.190 |
Why?
| | Child | 9 | 2020 | 20655 | 0.190 |
Why?
| | Double-Blind Method | 2 | 2018 | 1848 | 0.180 |
Why?
| | Facility Regulation and Control | 1 | 2000 | 3 | 0.180 |
Why?
| | Long QT Syndrome | 1 | 2022 | 66 | 0.180 |
Why?
| | Sodium, Dietary | 1 | 2021 | 39 | 0.180 |
Why?
| | Administrative Personnel | 1 | 2020 | 29 | 0.180 |
Why?
| | Sierra Leone | 1 | 2020 | 3 | 0.180 |
Why?
| | Medical Oncology | 1 | 2023 | 271 | 0.180 |
Why?
| | Botswana | 1 | 2020 | 8 | 0.180 |
Why?
| | Healthcare Disparities | 2 | 2021 | 579 | 0.180 |
Why?
| | Patient Isolation | 1 | 2020 | 16 | 0.170 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 2051 | 0.170 |
Why?
| | United States Agency for Healthcare Research and Quality | 1 | 2020 | 10 | 0.170 |
Why?
| | Artificial Intelligence | 1 | 2023 | 244 | 0.170 |
Why?
| | Antidepressive Agents | 1 | 2002 | 221 | 0.170 |
Why?
| | Whooping Cough | 1 | 2020 | 48 | 0.170 |
Why?
| | Thiadiazines | 1 | 2020 | 2 | 0.170 |
Why?
| | Codes of Ethics | 2 | 2018 | 17 | 0.170 |
Why?
| | Hemorrhagic Fever, Ebola | 1 | 2020 | 35 | 0.170 |
Why?
| | Faculty, Medical | 2 | 2000 | 262 | 0.170 |
Why?
| | Organizational Case Studies | 3 | 2010 | 75 | 0.170 |
Why?
| | Psychology, Adolescent | 1 | 2000 | 63 | 0.170 |
Why?
| | Medicare | 1 | 2005 | 715 | 0.170 |
Why?
| | Food Safety | 1 | 2020 | 18 | 0.170 |
Why?
| | Postpartum Hemorrhage | 1 | 2019 | 16 | 0.160 |
Why?
| | Reproduction | 1 | 2021 | 199 | 0.160 |
Why?
| | Dabigatran | 1 | 2019 | 21 | 0.160 |
Why?
| | Surveys and Questionnaires | 8 | 2024 | 5362 | 0.160 |
Why?
| | Middle Aged | 7 | 2023 | 30889 | 0.160 |
Why?
| | Social Control, Formal | 1 | 2019 | 11 | 0.160 |
Why?
| | Models, Theoretical | 2 | 2020 | 542 | 0.160 |
Why?
| | Nutritive Value | 1 | 2019 | 36 | 0.160 |
Why?
| | Secondary Prevention | 1 | 2020 | 219 | 0.160 |
Why?
| | Organizational Affiliation | 2 | 2000 | 8 | 0.160 |
Why?
| | Food Supply | 1 | 2020 | 72 | 0.160 |
Why?
| | Computer Security | 1 | 2019 | 19 | 0.160 |
Why?
| | Chronic Pain | 1 | 2023 | 254 | 0.160 |
Why?
| | Stakeholder Participation | 1 | 2019 | 77 | 0.150 |
Why?
| | Random Allocation | 2 | 2024 | 343 | 0.150 |
Why?
| | Retrospective Studies | 5 | 2022 | 14454 | 0.150 |
Why?
| | Schools | 1 | 2002 | 438 | 0.150 |
Why?
| | Health Risk Behaviors | 1 | 2018 | 16 | 0.150 |
Why?
| | Information Storage and Retrieval | 2 | 2015 | 107 | 0.150 |
Why?
| | Morphine | 4 | 1987 | 126 | 0.150 |
Why?
| | Intersectoral Collaboration | 1 | 2018 | 61 | 0.150 |
Why?
| | Oral Health | 1 | 2020 | 129 | 0.150 |
Why?
| | Professional Practice | 1 | 1998 | 64 | 0.150 |
Why?
| | Practice Management, Medical | 1 | 2018 | 36 | 0.150 |
Why?
| | Eating | 1 | 2020 | 368 | 0.150 |
Why?
| | Statistics as Topic | 1 | 2019 | 302 | 0.150 |
Why?
| | Urinary Bladder, Overactive | 1 | 2018 | 20 | 0.140 |
Why?
| | Pyridones | 1 | 2019 | 159 | 0.140 |
Why?
| | United Kingdom | 3 | 2022 | 257 | 0.140 |
Why?
| | Costs and Cost Analysis | 2 | 2022 | 199 | 0.140 |
Why?
| | Tuberculosis | 1 | 2020 | 271 | 0.140 |
Why?
| | Rivaroxaban | 1 | 2019 | 253 | 0.140 |
Why?
| | Health Resources | 1 | 2018 | 112 | 0.140 |
Why?
| | Informed Consent | 2 | 2024 | 168 | 0.140 |
Why?
| | Linear Models | 2 | 2020 | 813 | 0.130 |
Why?
| | Quality of Life | 3 | 2023 | 2680 | 0.130 |
Why?
| | Food Handling | 1 | 2016 | 59 | 0.130 |
Why?
| | Triclosan | 1 | 2016 | 9 | 0.130 |
Why?
| | Patient Selection | 2 | 2011 | 663 | 0.130 |
Why?
| | Patient Participation | 2 | 1997 | 410 | 0.130 |
Why?
| | Nutrition Assessment | 1 | 2016 | 85 | 0.130 |
Why?
| | Brain Chemistry | 2 | 1988 | 115 | 0.130 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 418 | 0.130 |
Why?
| | Environmental Monitoring | 1 | 2018 | 322 | 0.130 |
Why?
| | Judgment | 1 | 2016 | 56 | 0.130 |
Why?
| | Leadership | 1 | 2020 | 356 | 0.130 |
Why?
| | Information Centers | 1 | 1995 | 4 | 0.130 |
Why?
| | Endocrine Disruptors | 1 | 2016 | 40 | 0.130 |
Why?
| | Epidemiologic Research Design | 1 | 2016 | 28 | 0.130 |
Why?
| | Pyrazoles | 1 | 2019 | 404 | 0.130 |
Why?
| | Thyroxine | 1 | 2016 | 62 | 0.130 |
Why?
| | Pregnancy | 6 | 2019 | 6357 | 0.130 |
Why?
| | 5-Hydroxytryptophan | 2 | 1987 | 20 | 0.130 |
Why?
| | Venous Thromboembolism | 1 | 2019 | 271 | 0.120 |
Why?
| | Malnutrition | 1 | 2016 | 79 | 0.120 |
Why?
| | Calcium Channel Blockers | 1 | 1996 | 123 | 0.120 |
Why?
| | Health | 1 | 2015 | 73 | 0.120 |
Why?
| | Sex Factors | 2 | 2012 | 1945 | 0.120 |
Why?
| | Infant, Newborn | 2 | 2020 | 5687 | 0.120 |
Why?
| | Ranibizumab | 1 | 2014 | 20 | 0.120 |
Why?
| | Depressive Disorder | 1 | 2018 | 360 | 0.120 |
Why?
| | Medical Informatics | 1 | 2015 | 99 | 0.120 |
Why?
| | Italy | 1 | 2014 | 97 | 0.110 |
Why?
| | Hypertension | 2 | 2010 | 1235 | 0.110 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3020 | 0.110 |
Why?
| | Adverse Drug Reaction Reporting Systems | 2 | 2011 | 74 | 0.110 |
Why?
| | Legislation, Food | 1 | 2013 | 2 | 0.110 |
Why?
| | Food Additives | 1 | 2013 | 7 | 0.110 |
Why?
| | Nursing Staff, Hospital | 1 | 2016 | 149 | 0.110 |
Why?
| | Bevacizumab | 1 | 2014 | 129 | 0.110 |
Why?
| | Equipment Safety | 2 | 2010 | 39 | 0.110 |
Why?
| | History, 20th Century | 2 | 2007 | 291 | 0.110 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1204 | 0.110 |
Why?
| | Vaccination | 1 | 2022 | 1346 | 0.110 |
Why?
| | Lung Neoplasms | 2 | 2005 | 2328 | 0.110 |
Why?
| | Search Engine | 1 | 2013 | 10 | 0.110 |
Why?
| | Physician's Role | 1 | 2015 | 206 | 0.110 |
Why?
| | Nursing Homes | 1 | 2015 | 152 | 0.100 |
Why?
| | Clinical Protocols | 2 | 2009 | 252 | 0.100 |
Why?
| | Health Services Research | 1 | 1996 | 391 | 0.100 |
Why?
| | Antipsychotic Agents | 1 | 2015 | 191 | 0.100 |
Why?
| | Wounds and Injuries | 1 | 2019 | 707 | 0.100 |
Why?
| | Health Planning Guidelines | 1 | 2012 | 24 | 0.100 |
Why?
| | Total Quality Management | 1 | 2012 | 60 | 0.100 |
Why?
| | Reimbursement Mechanisms | 1 | 2013 | 84 | 0.100 |
Why?
| | Gastroenterology | 1 | 2014 | 174 | 0.100 |
Why?
| | Legislation, Drug | 2 | 2010 | 77 | 0.090 |
Why?
| | Maryland | 2 | 2002 | 45 | 0.090 |
Why?
| | Americas | 1 | 2011 | 21 | 0.090 |
Why?
| | Switzerland | 1 | 2011 | 35 | 0.090 |
Why?
| | Pain | 3 | 2023 | 757 | 0.090 |
Why?
| | Aged | 7 | 2014 | 21953 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 999 | 0.090 |
Why?
| | Comprehension | 1 | 2013 | 164 | 0.090 |
Why?
| | Libraries | 1 | 2011 | 4 | 0.090 |
Why?
| | Cardiac Resynchronization Therapy Devices | 1 | 2011 | 11 | 0.090 |
Why?
| | Eclampsia | 1 | 2010 | 4 | 0.090 |
Why?
| | Guatemala | 1 | 2012 | 311 | 0.090 |
Why?
| | Health Services Needs and Demand | 1 | 2013 | 264 | 0.090 |
Why?
| | Tocolytic Agents | 1 | 2010 | 15 | 0.090 |
Why?
| | Self Concept | 1 | 2012 | 242 | 0.090 |
Why?
| | Magnesium Sulfate | 1 | 2010 | 18 | 0.090 |
Why?
| | Mammography | 1 | 2012 | 146 | 0.090 |
Why?
| | Quality Assurance, Health Care | 3 | 2012 | 316 | 0.090 |
Why?
| | Time Factors | 1 | 2021 | 6482 | 0.090 |
Why?
| | Prevalence | 3 | 2022 | 2547 | 0.090 |
Why?
| | Serotonin | 3 | 1987 | 317 | 0.090 |
Why?
| | Education, Pharmacy, Continuing | 1 | 2010 | 3 | 0.090 |
Why?
| | Age Factors | 2 | 2012 | 3103 | 0.090 |
Why?
| | Educational Status | 1 | 2012 | 470 | 0.090 |
Why?
| | Health Facilities | 1 | 2010 | 79 | 0.080 |
Why?
| | Multicenter Studies as Topic | 1 | 2011 | 285 | 0.080 |
Why?
| | Rats, Inbred Strains | 5 | 1988 | 356 | 0.080 |
Why?
| | Health Surveys | 1 | 2012 | 492 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2014 | 1936 | 0.080 |
Why?
| | Mandatory Programs | 1 | 2009 | 14 | 0.080 |
Why?
| | Mental Disorders | 1 | 2018 | 1027 | 0.080 |
Why?
| | Radiology | 1 | 2012 | 161 | 0.080 |
Why?
| | Prostheses and Implants | 1 | 2010 | 136 | 0.080 |
Why?
| | Growth Hormone | 2 | 1987 | 96 | 0.080 |
Why?
| | Disasters | 1 | 2010 | 91 | 0.080 |
Why?
| | Vinyl Chloride | 1 | 2009 | 2 | 0.080 |
Why?
| | Heart-Assist Devices | 1 | 2015 | 537 | 0.080 |
Why?
| | Breast Feeding | 2 | 2024 | 422 | 0.080 |
Why?
| | Multivariate Analysis | 2 | 2006 | 1484 | 0.080 |
Why?
| | Lead Poisoning | 1 | 2009 | 19 | 0.080 |
Why?
| | Financing, Government | 1 | 2009 | 42 | 0.080 |
Why?
| | Consensus | 2 | 2024 | 613 | 0.080 |
Why?
| | Placebos | 1 | 2009 | 201 | 0.080 |
Why?
| | Patient Compliance | 2 | 2003 | 560 | 0.080 |
Why?
| | Rats | 8 | 2016 | 5165 | 0.080 |
Why?
| | Learning | 1 | 2012 | 396 | 0.080 |
Why?
| | Silicosis | 1 | 2009 | 27 | 0.080 |
Why?
| | Pre-Eclampsia | 1 | 2010 | 185 | 0.080 |
Why?
| | Methadone | 2 | 1987 | 90 | 0.070 |
Why?
| | Smartphone | 2 | 2019 | 88 | 0.070 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1212 | 0.070 |
Why?
| | Helsinki Declaration | 1 | 2007 | 2 | 0.070 |
Why?
| | Infant | 3 | 2024 | 8914 | 0.070 |
Why?
| | Coronary Disease | 1 | 2010 | 382 | 0.070 |
Why?
| | Motivation | 2 | 2020 | 546 | 0.070 |
Why?
| | Patient Care Team | 2 | 2003 | 605 | 0.070 |
Why?
| | Health Plan Implementation | 1 | 2008 | 136 | 0.070 |
Why?
| | Logistic Models | 2 | 2006 | 1974 | 0.070 |
Why?
| | Financing, Organized | 3 | 2003 | 30 | 0.070 |
Why?
| | Reference Values | 1 | 2009 | 776 | 0.070 |
Why?
| | Receptors, Dopamine | 1 | 1987 | 16 | 0.070 |
Why?
| | Propylamines | 1 | 1987 | 11 | 0.070 |
Why?
| | Persuasive Communication | 1 | 2007 | 13 | 0.070 |
Why?
| | Receptors, Serotonin | 1 | 1987 | 33 | 0.070 |
Why?
| | Consumer Behavior | 2 | 2004 | 67 | 0.070 |
Why?
| | Cardiology | 1 | 2009 | 260 | 0.070 |
Why?
| | Longitudinal Studies | 2 | 2022 | 2710 | 0.070 |
Why?
| | Adolescent | 4 | 2010 | 20179 | 0.070 |
Why?
| | Culture | 1 | 2007 | 123 | 0.070 |
Why?
| | Regression Analysis | 1 | 2009 | 978 | 0.070 |
Why?
| | Fluoxetine | 1 | 1987 | 52 | 0.070 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1986 | 24 | 0.060 |
Why?
| | Hypothalamus | 1 | 1987 | 144 | 0.060 |
Why?
| | United States Public Health Service | 1 | 2006 | 9 | 0.060 |
Why?
| | Patient Readmission | 1 | 1991 | 664 | 0.060 |
Why?
| | Mothers | 1 | 2012 | 729 | 0.060 |
Why?
| | Ethics, Medical | 2 | 1999 | 78 | 0.060 |
Why?
| | Catecholamines | 1 | 1986 | 97 | 0.060 |
Why?
| | Geography | 1 | 2006 | 186 | 0.060 |
Why?
| | United States Government Agencies | 1 | 2005 | 6 | 0.060 |
Why?
| | Prospective Studies | 5 | 2020 | 7036 | 0.060 |
Why?
| | Forms and Records Control | 1 | 2005 | 22 | 0.060 |
Why?
| | Health Maintenance Organizations | 2 | 2003 | 99 | 0.060 |
Why?
| | Economic Competition | 1 | 2004 | 14 | 0.060 |
Why?
| | Alkaloids | 1 | 2004 | 25 | 0.060 |
Why?
| | Paper | 1 | 2024 | 10 | 0.060 |
Why?
| | Laboratory Personnel | 1 | 2024 | 4 | 0.060 |
Why?
| | Academies and Institutes | 1 | 2005 | 47 | 0.060 |
Why?
| | Animal Welfare | 1 | 2024 | 13 | 0.060 |
Why?
| | Anticonvulsants | 1 | 2006 | 197 | 0.060 |
Why?
| | Mass Screening | 1 | 2012 | 1146 | 0.060 |
Why?
| | Compassion Fatigue | 1 | 2024 | 29 | 0.060 |
Why?
| | Health Care Coalitions | 1 | 2004 | 9 | 0.060 |
Why?
| | Genetic Engineering | 1 | 2004 | 88 | 0.060 |
Why?
| | Cyproheptadine | 4 | 1987 | 6 | 0.060 |
Why?
| | Occupational Stress | 1 | 2024 | 39 | 0.050 |
Why?
| | Odds Ratio | 2 | 2020 | 1023 | 0.050 |
Why?
| | Emergency Service, Hospital | 2 | 2014 | 1901 | 0.050 |
Why?
| | Patient Safety | 2 | 2019 | 287 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2011 | 974 | 0.050 |
Why?
| | Labor Unions | 1 | 2003 | 3 | 0.050 |
Why?
| | United States Occupational Safety and Health Administration | 1 | 2003 | 8 | 0.050 |
Why?
| | Planning Techniques | 1 | 2003 | 16 | 0.050 |
Why?
| | Liability, Legal | 4 | 1995 | 40 | 0.050 |
Why?
| | Inservice Training | 2 | 2016 | 111 | 0.050 |
Why?
| | Japan | 1 | 2002 | 96 | 0.050 |
Why?
| | Polyvinyls | 1 | 2002 | 19 | 0.050 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1984 | 475 | 0.050 |
Why?
| | Awareness | 1 | 2003 | 98 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2022 | 3 | 0.050 |
Why?
| | Databases as Topic | 1 | 2002 | 59 | 0.050 |
Why?
| | Administration, Cutaneous | 1 | 2002 | 122 | 0.050 |
Why?
| | Polymethacrylic Acids | 1 | 2002 | 62 | 0.050 |
Why?
| | Ethics, Business | 1 | 2001 | 2 | 0.050 |
Why?
| | Point-of-Care Systems | 1 | 2023 | 146 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 1988 | 1355 | 0.050 |
Why?
| | Telephone | 1 | 2002 | 168 | 0.050 |
Why?
| | Heart Diseases | 1 | 2005 | 345 | 0.050 |
Why?
| | Patents as Topic | 1 | 2021 | 1 | 0.050 |
Why?
| | Feedback | 1 | 2002 | 159 | 0.050 |
Why?
| | Varenicline | 1 | 2021 | 26 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2012 | 7033 | 0.050 |
Why?
| | Hand Hygiene | 1 | 2020 | 8 | 0.040 |
Why?
| | Perception | 1 | 2003 | 338 | 0.040 |
Why?
| | Radiologists | 1 | 2020 | 41 | 0.040 |
Why?
| | Conservation of Natural Resources | 1 | 2002 | 105 | 0.040 |
Why?
| | Journalism, Medical | 1 | 2000 | 5 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 2009 | 1212 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2000 | 58 | 0.040 |
Why?
| | Dentistry | 1 | 2020 | 9 | 0.040 |
Why?
| | Computer Graphics | 1 | 2020 | 41 | 0.040 |
Why?
| | Music | 1 | 2000 | 39 | 0.040 |
Why?
| | Freedom | 1 | 2000 | 15 | 0.040 |
Why?
| | Masks | 1 | 2020 | 59 | 0.040 |
Why?
| | International Agencies | 1 | 2020 | 29 | 0.040 |
Why?
| | Social Values | 1 | 2000 | 34 | 0.040 |
Why?
| | Death | 1 | 2000 | 121 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2012 | 2132 | 0.040 |
Why?
| | Social Perception | 1 | 2001 | 104 | 0.040 |
Why?
| | Cost of Illness | 1 | 2022 | 277 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2020 | 67 | 0.040 |
Why?
| | Ethics | 2 | 1996 | 6 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1563 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 604 | 0.040 |
Why?
| | Insulin | 1 | 2009 | 2315 | 0.040 |
Why?
| | Foundations | 1 | 2018 | 24 | 0.040 |
Why?
| | Employment | 1 | 2020 | 165 | 0.040 |
Why?
| | Contracts | 1 | 1998 | 10 | 0.040 |
Why?
| | Social Behavior | 1 | 2001 | 289 | 0.040 |
Why?
| | Fiji | 1 | 2017 | 3 | 0.040 |
Why?
| | Health Status Indicators | 1 | 1998 | 166 | 0.030 |
Why?
| | Technology Assessment, Biomedical | 1 | 1997 | 29 | 0.030 |
Why?
| | Forecasting | 1 | 2018 | 358 | 0.030 |
Why?
| | Sampling Studies | 1 | 1996 | 96 | 0.030 |
Why?
| | Animals, Newborn | 3 | 1987 | 803 | 0.030 |
Why?
| | Capacity Building | 1 | 2016 | 59 | 0.030 |
Why?
| | Diffusion of Innovation | 1 | 1997 | 96 | 0.030 |
Why?
| | CD-ROM | 1 | 1995 | 6 | 0.030 |
Why?
| | Medical Informatics Applications | 1 | 1995 | 7 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2024 | 1059 | 0.030 |
Why?
| | Patient Discharge | 1 | 2002 | 853 | 0.030 |
Why?
| | Models, Statistical | 1 | 2020 | 621 | 0.030 |
Why?
| | Anti-Infective Agents, Local | 1 | 2016 | 42 | 0.030 |
Why?
| | Developed Countries | 1 | 1995 | 33 | 0.030 |
Why?
| | Air Pollution | 1 | 2018 | 214 | 0.030 |
Why?
| | Child, Preschool | 1 | 2010 | 10384 | 0.030 |
Why?
| | Regional Medical Programs | 1 | 1995 | 4 | 0.030 |
Why?
| | Software | 1 | 2020 | 608 | 0.030 |
Why?
| | Analysis of Variance | 1 | 1998 | 1269 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2009 | 2429 | 0.030 |
Why?
| | Communication Barriers | 1 | 1996 | 98 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2022 | 1421 | 0.030 |
Why?
| | Drugs, Investigational | 1 | 2015 | 32 | 0.030 |
Why?
| | Influenza, Human | 1 | 2020 | 601 | 0.030 |
Why?
| | Poison Control Centers | 1 | 1995 | 89 | 0.030 |
Why?
| | Palliative Care | 1 | 2000 | 713 | 0.030 |
Why?
| | Education, Medical, Undergraduate | 1 | 1995 | 176 | 0.030 |
Why?
| | Drug Contamination | 1 | 2013 | 50 | 0.030 |
Why?
| | Drug Stability | 1 | 2013 | 144 | 0.030 |
Why?
| | Solubility | 1 | 2013 | 229 | 0.020 |
Why?
| | Family Practice | 1 | 1996 | 455 | 0.020 |
Why?
| | Hospital Bed Capacity, 300 to 499 | 1 | 1991 | 4 | 0.020 |
Why?
| | Precision Medicine | 1 | 2015 | 384 | 0.020 |
Why?
| | Dementia | 1 | 2015 | 227 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 316 | 0.020 |
Why?
| | Dissent and Disputes | 1 | 2011 | 17 | 0.020 |
Why?
| | National Health Programs | 1 | 2010 | 17 | 0.020 |
Why?
| | Zambia | 1 | 2010 | 55 | 0.020 |
Why?
| | Observer Variation | 1 | 1991 | 312 | 0.020 |
Why?
| | Referral and Consultation | 2 | 1995 | 727 | 0.020 |
Why?
| | Chronic Disease | 1 | 2016 | 1705 | 0.020 |
Why?
| | Training Support | 1 | 2010 | 28 | 0.020 |
Why?
| | Midwifery | 1 | 2010 | 48 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 1991 | 205 | 0.020 |
Why?
| | San Francisco | 3 | 1995 | 51 | 0.020 |
Why?
| | Endpoint Determination | 1 | 2009 | 75 | 0.020 |
Why?
| | beta-Endorphin | 1 | 1988 | 8 | 0.020 |
Why?
| | Obstetrics | 1 | 2010 | 161 | 0.020 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 1988 | 59 | 0.020 |
Why?
| | Migraine Disorders | 1 | 2009 | 82 | 0.020 |
Why?
| | Aging | 3 | 1987 | 1750 | 0.020 |
Why?
| | Molecular Weight | 1 | 1988 | 331 | 0.020 |
Why?
| | Iodine Radioisotopes | 1 | 1988 | 142 | 0.020 |
Why?
| | Enkephalin, D-Penicillamine (2,5)- | 1 | 1987 | 1 | 0.020 |
Why?
| | 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 1 | 1987 | 3 | 0.020 |
Why?
| | Receptors, Opioid, kappa | 1 | 1987 | 10 | 0.020 |
Why?
| | Endorphins | 1 | 1987 | 8 | 0.020 |
Why?
| | Enkephalins | 1 | 1987 | 16 | 0.020 |
Why?
| | Dynorphins | 1 | 1987 | 9 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2012 | 369 | 0.020 |
Why?
| | Hydrazines | 1 | 1987 | 34 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 1987 | 56 | 0.020 |
Why?
| | Pyrrolidines | 1 | 1987 | 68 | 0.020 |
Why?
| | p-Chloroamphetamine | 1 | 1987 | 1 | 0.020 |
Why?
| | 5,7-Dihydroxytryptamine | 1 | 1987 | 3 | 0.020 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1987 | 25 | 0.020 |
Why?
| | Bipolar Disorder | 1 | 2009 | 235 | 0.020 |
Why?
| | Reserpine | 1 | 1986 | 3 | 0.020 |
Why?
| | Sympatholytics | 1 | 1986 | 14 | 0.020 |
Why?
| | Haloperidol | 1 | 1986 | 32 | 0.020 |
Why?
| | Corticosterone | 1 | 1987 | 214 | 0.020 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 1987 | 177 | 0.020 |
Why?
| | Norepinephrine | 1 | 1986 | 205 | 0.010 |
Why?
| | Piperazines | 1 | 1987 | 336 | 0.010 |
Why?
| | Electrochemistry | 1 | 1984 | 80 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1987 | 684 | 0.010 |
Why?
| | Clinical Competence | 1 | 2010 | 1013 | 0.010 |
Why?
| | Dopamine | 1 | 1986 | 285 | 0.010 |
Why?
| | Fetus | 1 | 1987 | 760 | 0.010 |
Why?
| | Reading | 1 | 2002 | 150 | 0.010 |
Why?
| | Pravastatin | 1 | 2000 | 26 | 0.010 |
Why?
| | Alendronate | 1 | 2000 | 15 | 0.010 |
Why?
| | Television | 1 | 2000 | 74 | 0.010 |
Why?
| | Outpatients | 2 | 1993 | 366 | 0.010 |
Why?
| | Anticholesteremic Agents | 1 | 2000 | 146 | 0.010 |
Why?
| | European Union | 1 | 1997 | 10 | 0.010 |
Why?
| | Aspirin | 1 | 2000 | 376 | 0.010 |
Why?
| | Clinical Trials, Phase IV as Topic | 1 | 1995 | 3 | 0.010 |
Why?
| | Fees, Medical | 1 | 1995 | 9 | 0.010 |
Why?
| | Home Nursing | 1 | 1995 | 26 | 0.010 |
Why?
| | Physicians' Offices | 1 | 1995 | 17 | 0.010 |
Why?
| | Hotlines | 1 | 1995 | 31 | 0.010 |
Why?
| | Hospital Charges | 1 | 1995 | 41 | 0.010 |
Why?
| | Propofol | 1 | 1995 | 52 | 0.010 |
Why?
| | Poisoning | 1 | 1995 | 111 | 0.010 |
Why?
| | Insurance, Health | 1 | 1995 | 267 | 0.010 |
Why?
| | Medication Errors | 1 | 1993 | 95 | 0.010 |
Why?
| | Frail Elderly | 1 | 1993 | 121 | 0.010 |
Why?
| | Hospitals, Community | 1 | 1992 | 49 | 0.010 |
Why?
| | Medical Staff, Hospital | 1 | 1992 | 77 | 0.010 |
Why?
| | Curriculum | 1 | 1995 | 917 | 0.000 |
Why?
| | Endocrine Glands | 1 | 1987 | 15 | 0.000 |
Why?
| | Alcoholic Beverages | 1 | 1987 | 20 | 0.000 |
Why?
| | Narcotics | 1 | 1987 | 45 | 0.000 |
Why?
| | Maternal-Fetal Exchange | 1 | 1987 | 161 | 0.000 |
Why?
| | Follow-Up Studies | 1 | 1995 | 4892 | 0.000 |
Why?
| | Cocaine | 1 | 1987 | 148 | 0.000 |
Why?
| | Marijuana Abuse | 1 | 1987 | 229 | 0.000 |
Why?
| | Child Development | 1 | 1987 | 452 | 0.000 |
Why?
| | Disease Models, Animal | 1 | 1987 | 3937 | 0.000 |
Why?
|
|
Bero's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|